AU
UK
CA
NZ
IND
US
Last update at 2026-06-04T18:05:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -140.10900M | -160.86800M | -100.83700M | -107.49400M | -71.31700M |
| Minority interest | - | - | - | - | - |
| Net income | -140.10900M | -160.86800M | -100.83700M | -101.07600M | -68.29700M |
| Selling general administrative | 49.06M | 46.58M | 36.49M | 32.91M | 28.01M |
| Selling and marketing expenses | - | - | 5.75M | - | - |
| Gross profit | 77.58M | 0.04M | -76.37300M | 3.13M | 18.04M |
| Reconciled depreciation | 7.62M | 6.71M | 5.62M | 3.88M | 3.02M |
| Ebit | -159.54700M | -187.84100M | -112.86700M | -113.91200M | -74.35300M |
| Ebitda | -151.92200M | -181.13600M | -108.66300M | -110.03200M | -71.33300M |
| Depreciation and amortization | 7.62M | 6.71M | 4.20M | 3.88M | 3.02M |
| Non operating income net other | - | - | - | 2.54M | 0.02M |
| Operating income | -159.54700M | -187.84100M | -112.86700M | -110.03200M | -71.33300M |
| Other operating expenses | 244.76M | 187.88M | 133.59M | 113.16M | 89.37M |
| Interest expense | - | - | - | 6.42M | 3.04M |
| Tax provision | - | - | - | - | - |
| Interest income | 19.48M | 27.05M | 9.17M | 2.57M | 0.14M |
| Net interest income | 19.48M | 27.05M | 9.17M | 2.57M | 0.14M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | - | 5.58M | -6.41800M | -3.02000M |
| Total revenue | 85.21M | 0.04M | 20.72M | 3.13M | 18.04M |
| Total operating expenses | 237.13M | 187.88M | 36.49M | 113.16M | 89.37M |
| Cost of revenue | 7.62M | 6.71M | 97.10M | - | - |
| Total other income expense net | 19.44M | 26.97M | 12.03M | 2.54M | 0.02M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -140.10900M | -160.86800M | -95.93300M | -107.49400M | -71.31700M |
| Net income applicable to common shares | - | - | - | -107.49400M | -71.31700M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 566.71M | 560.38M | 339.89M | 261.85M | 353.49M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 10.48M | 10.05M | 8.36M | 6.96M | 8.46M |
| Total liab | 61.05M | 49.78M | 32.06M | 30.51M | 560.48M |
| Total stockholder equity | 505.66M | 510.61M | 307.83M | -314.49000M | -206.99600M |
| Deferred long term liab | - | - | - | 0.21M | 0.21M |
| Other current liab | 26.87M | 18.87M | 12.01M | 8.87M | 7.74M |
| Common stock | 0.00600M | 0.00500M | 0.00400M | 0.00300M | 0.00300M |
| Capital stock | 0.00600M | 0.00500M | 0.00400M | 0.00300M | 0.00300M |
| Retained earnings | -716.30400M | -576.19500M | -415.32700M | -314.49000M | -206.99600M |
| Other liab | - | - | - | 1.31M | 2.83M |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | 1.08M | 0.60M |
| Cash | 60.24M | 149.34M | 249.11M | 218.64M | 315.43M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 43.98M | 29.15M | 18.95M | 15.73M | 16.34M |
| Current deferred revenue | 0.36M | 0.26M | 0.27M | 0.88M | 2.60M |
| Net debt | -38.82800M | -124.73000M | -234.43700M | -202.51800M | -298.98100M |
| Short term debt | 5.59M | 5.64M | 3.15M | 2.65M | 1.23M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 21.41M | 24.61M | 14.67M | 16.12M | 16.45M |
| Other stockholder equity | 1221.23M | 1086.57M | 723.14M | 1.19M | 0.42M |
| Property plant equipment | - | - | - | 22.26M | 28.95M |
| Total current assets | 413.13M | 434.93M | 296.59M | 220.51M | 315.43M |
| Long term investments | 111.38M | 80.58M | 10.95M | 4.91M | 67.65M |
| Net tangible assets | - | - | - | 231.34M | 319.11M |
| Short term investments | 342.41M | 275.54M | 39.12M | 161.20M | 94.78M |
| Net receivables | - | - | - | 0.70M | 0.05M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | -8.50300M |
| Accounts payable | 11.16M | 4.39M | 3.52M | 3.32M | 4.76M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.73M | 0.23M | 0.02M | -1.19600M | -0.42300M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.00300M | 0.00300M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -314.49000M | -206.99600M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 120.57M | 4.26M | 0.68M | 1.08M | -58.54700M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 153.58M | 125.45M | 43.30M | 41.34M | 38.06M |
| Capital lease obligations | 21.41M | 24.61M | 14.67M | 16.12M | 16.45M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -92.43700M | -302.43700M | 86.62M | -5.51400M | -163.57000M |
| Change to liabilities | - | - | - | 0.85M | -12.43700M |
| Total cashflows from investing activities | -92.97300M | -302.43700M | 115.72M | -17.05000M | -172.68000M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 112.96M | 337.25M | 156.83M | 3.08M | 118.09M |
| Change to operating activities | - | - | - | 3.38M | -4.53600M |
| Net income | -140.10900M | -160.86800M | -100.83700M | -107.49400M | -71.31700M |
| Change in cash | -89.09500M | -99.77200M | 196.76M | -100.65000M | -123.72500M |
| Begin period cash flow | 149.34M | 249.11M | 52.35M | 153.00M | 276.73M |
| End period cash flow | 60.24M | 149.34M | 249.11M | 52.35M | 153.00M |
| Total cash from operating activities | -109.08200M | -134.58500M | -75.79200M | -86.68500M | -69.13400M |
| Issuance of capital stock | 110.72M | 331.41M | 148.34M | 0.00000M | 114.30M |
| Depreciation | 7.62M | 6.71M | 5.75M | 3.88M | 3.02M |
| Other cashflows from investing activities | -0.53600M | -3.78600M | 173.29M | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | -4.53600M |
| Change to account receivables | - | - | 0.00000M | 0.05M | 1.44M |
| Sale purchase of stock | 7.50M | - | - | -0.46800M | 114.73M |
| Other cashflows from financing activities | 112.96M | 5.84M | 8.49M | 0.35M | 3.79M |
| Change to netincome | - | - | - | 17.12M | 14.70M |
| Capital expenditures | 0.54M | 3.79M | 2.77M | 11.54M | 9.11M |
| Change receivables | - | - | - | 0.05M | 1.44M |
| Cash flows other operating | - | - | - | -0.66600M | -18.36300M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | -100.65000M | -123.72500M |
| Change in working capital | 6.17M | 0.54M | 0.63M | -1.33600M | -15.53400M |
| Stock based compensation | 22.02M | 26.12M | 19.66M | 17.12M | 13.80M |
| Other non cash items | -4.78600M | -7.07500M | -0.99900M | 1.14M | 0.90M |
| Free cash flow | -109.08200M | -138.37100M | -78.56300M | -98.22100M | -78.24400M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| FDMT 4D Molecular Therapeutics Inc |
0.33 3.46% | 9.86 | - | - | 5.85 | 1.02 | 1.56 | -3.551 |
| NVO Novo Nordisk A/S |
1.81 4.32% | 43.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.78 4.23% | 44.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
12.68 2.96% | 441.01 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
6.44 1.04% | 625.39 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
5858 Horton Street, EmeryVille, CA, United States, 94608
| Name | Title | Year Born |
|---|---|---|
| Dr. John F. Milligan Ph.D. | Exec. Chairman | 1961 |
| Dr. David H. Kirn M.D. | Co-Founder, CEO & Director | 1962 |
| Ms. Theresa Janke | Co-Founder & Chief of Staff | 1975 |
| Mr. August J. Moretti Esq., J.D. | Chief Financial Officer | 1951 |
| Dr. Fred Kamal Ph.D. | Pres & COO | 1963 |
| Mike Zanoni | VP of Investor Relations | NA |
| Dr. Scott P. Bizily J.D., Ph.D. | Chief Legal & HR Officer and Corp. Sec. | 1972 |
| Dr. Robert S. Fishman | Chief Medical Officer & Therapeutic Area Head of Pulmonology | 1962 |
| Dr. Raphael Schiffmann M.D. | Sr. VP & Therapeutic Area Head of Cardiology | NA |
| Dr. Robert Y. Kim M.B.A., M.D. | Sr. VP & Clinical Therapeutic Area Head of Ophthalmology | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...